Conformis to Present at J.P. Morgan 33rd Annual Healthcare Conference

Bedford, Mass. – January 5, 2015 – Conformis, Inc., a medical device company providing the only truly customized knee replacement implant systems, today announced Philipp Lang, MD, MBA, Chairman and CEO of Conformis, will present at the 33rd Annual J.P. Morgan Healthcare Conference. Dr. Lang will highlight advantages of customized implants to patients, surgeons, hospitals and payers beginning at 4:00 p.m. PT on Wednesday, January 14, 2015 at the Westin St. Francis in San Francisco, CA.

About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company, specializing in orthopedics, that designs and manufactures individually made, customized knee implants with a full set of single-use, pre-sterilized instrumentation for each and every patient. Its proprietary technology is supported by more than 400 patents and patent applications. Conformis’ award winning partial and total knee replacement solutions, the iUni^® G2, iDuo^® G2 and iTotal^® G2, are individually designed based on the patient’s unique anatomy. Potential advantages compared to traditional off-the-shelf implants include faster recovery, shorter hospital stay, less blood loss, more bone preservation, and better functional outcomes with more natural feeling knees. Conformis products are provided in a pre-sterilized single package delivery system that can help hospitals reduce costs and treat more patients by reducing instrument re-sterilization costs and shortening set-up, procedure and turnover times. The iUni^® G2, iDuo^® G2 and iTotal^® G2, have been cleared by the U.S. FDA and are CE Marked in Europe.

Conformis is the leader in additive manufacturing in the orthopedic and medical device space. Conformis is the only orthopedic company that offers Just-In-Time (JIT) manufacturing with a single-package delivery system, resulting in greatly enhanced use of working capital.

Conformis technology is broadly applicable to all joints. The company is expanding into new applications and indications.

For more information visit www.conformis.com, follow @Conformis on Twitter, or ‘Like’ the Conformis Facebook page.